Back to home

Posts from "Issue3" tag

Biomarker Testing in NSCLC: How are we doing?

Beth Sandy, MSN, CRNP Beth Sandy, MSN, CRNP

As a nurse practitioner working in thoracic medical oncology, I have seen the changes in non-small cell lung cancer (NSCLC) change dramatically over the past 20 years that I have been practicing in this subspecialized field. Twenty years ago were the days of just paclitaxel and carboplatin as ...

Read more

How a Hematology Clinical Rotation Made me a Better Clinician

Rory Medley, PA-S Rory Medley, PA-S

Starting physician assistant (PA) school certainly presented its obstacles. How would I, a fresh college graduate, be able to tackle an intense medical education within the span of 27 months? The answer was almost too simple – one semester at a time. Fifteen months of didactic education came and ...

Read more

Recent Updates in the Treatment of Chronic-Graft-Versus-Host Disease

Fatima Khan, PharmD & Ila M. Saunders, PharmD, BCOP Fatima Khan, PharmD & Ila M. Saunders, PharmD, BCOP

Chronic graft-versus-host disease (cGVHD) is one of most common, yet severe, consequences of allogeneic hematopoietic stem cell transplantation. Occurring in up to 70% of patients, cGVHD is the leading cause of non-relapse mortality after allogeneic transplantation. Two new agents, belumosudil ...

Read more

When Sepsis isn’t Sepsis, Think HLH

Elizabeth S. Waxman, BSN, RN, MSN, ANP-BC Elizabeth S. Waxman, BSN, RN, MSN, ANP-BC

     Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal syndrome characterized by unchecked and persistent activation of cytotoxic T-cells and natural killer (NK) cells (Al-Samkari, Berliner, 2018). This uncontrolled immune response leads to increased secretion of inflammatory ...

Read more

Welcomed Changes: Promoting the right care at the right time

Bo Gamble Bo Gamble

Administrators, managers, and even clinicians have often used the terms “coding” and “billing” interchangeably. However, these terms in fact refer to separate pieces of the health care administrative structure. Services, the actual assistance or guidance provided to the patient, are matched to a ...

Read more

Sotorasib for KRAS G12C-Mutated Non-Small Cell Lung Cancer

Tori Gray, PharmD Candidate & Megan B May, PharmD, BCOP Tori Gray, PharmD Candidate & Megan B May, PharmD, BCOP

Non-small cell lung cancer (NSCLC) is the third most common type of cancer in the Unites States (US). It is known to harbor many types of mutations, making it particularly difficult to define the best treatment algorithm for a patient, especially after first line treatment. Over the last few ...

Read more

Tocilizumab alternatives in the management of cytokine release syndrome secondary to chimeric antigen receptor T therapies

Abigail Shockley, PharmD Abigail Shockley, PharmD

Chimeric antigen receptor T (CAR-T) therapies have resulted in durable remissions for patients with refractory hematologic malignancies; however, patients can experience many side effects following administration. Cytokine release syndrome (CRS) occurs as a result of rapid immune activation induced ...

Read more

Disease, Drugs and Infection: A Systematic Assessment of the Malignant Hematology Patient

Glen J Peterson, RN, DNP, ACNP & Jessica Casselberry, MSN, ANP-BC, AOCNP Glen J Peterson, RN, DNP, ACNP & Jessica Casselberry, MSN, ANP-BC, AOCNP

A thorough assessment of the patient with a hematologic malignancy is essential for the delivery of quality care. Almost every medical condition, symptom or complication will be caused by the patient’s underlying disease, a medication they have been prescribed, or an infection. Taking time to ...

Read more